GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1)

1 INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) Final version Adopted on 6 October 2021 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of ICH regions. i E8(R1) Document History E8 Code History Date E8 Approval by the Steering Committee under Step 4 and recommendation for adoption by ICH regulatory bodies.

2 17 July 1997 Revision of E8 Code History Date E8(R1) Adoption by the Regulatory Members of the ICH Assembly under Step 4. 6 October 2021 Legal notice: This document is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document.

3 Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided. The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document. The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

4 Ii ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) ICH Consensus Guideline TABLE OF CONTENTS 1. OBJECTIVES OF THIS DOCUMENT .. 1 2. GENERAL PRINCIPLES .. 2 Protection of CLINICAL Study Participants .. 2 Scientific Approach in CLINICAL Study Design, Planning, Conduct, Analysis, and 2 Patient Input into Drug Development .. 3 3. DESIGNING QUALITY INTO CLINICAL STUDIES .. 3 Quality by Design of CLINICAL STUDIES .. 3 Critical to Quality Factors .. 4 Approach to Identifying the Critical to Quality Factors .. 5 Establishing a Culture that Supports Open Dialogue.

5 5 Focusing on Activities Essential to the 5 Engaging Stakeholders in Study Design .. 6 Reviewing Critical to Quality Factors .. 6 Critical to Quality Factors in Operational Practice .. 6 4. DRUG DEVELOPMENT PLANNING .. 7 Quality of Investigational Medicinal Product .. 7 Non- CLINICAL STUDIES .. 8 CLINICAL STUDIES .. 8 Human Pharmacology .. 9 Exploratory and Confirmatory Safety and Efficacy 9 Special Populations .. 10 Post-Approval STUDIES .. 11 Additional Development .. 11 5. DESIGN ELEMENTS AND DATA SOURCES FOR CLINICAL STUDIES .. 11 Study Population.

6 12 Treatment Description .. 13 Choice of Control Group .. 13 Response Variables .. 14 Methods to Reduce Bias .. 14 Statistical Analysis .. 15 Study Data .. 16 6. CONDUCT, SAFETY MONITORING, AND REPORTING .. 18 Study Conduct .. 18 Protocol Adherence .. 18 Training .. 18 Data Management .. 18 Access to Interim Data .. 18 Participant Safety during Study Conduct .. 18 Safety Monitoring .. 18 Withdrawal Criteria .. 19 Data Monitoring Committee .. 19 Study 19 7. CONSIDERATIONS IN IDENTIFYING CRITICAL TO QUALITY FACTORS . 20 ANNEX: TYPES OF CLINICAL STUDIES .

7 22 ICH E8(R1) Guideline 1 1. OBJECTIVES OF THIS DOCUMENT CLINICAL STUDIES of medicinal products are conducted to provide information that can ultimately improve access to safe and effective products with meaningful impact on patients, while protecting those participating in the STUDIES . This document provides guidance on the CLINICAL development lifecycle, including designing quality into CLINICAL STUDIES , considering the broad range of CLINICAL study designs and data sources used. The ICH document " GENERAL CONSIDERATIONS for CLINICAL STUDIES " is intended to: 1.

8 Describe internationally accepted principles and practices in the design and conduct of CLINICAL STUDIES that will ensure the protection of study participants and facilitate acceptance of data and results by regulatory authorities 2. Provide guidance on the consideration of quality in the design and conduct of CLINICAL STUDIES across the product lifecycle, including the identification, during study planning, of factors that are critical to the quality of the study, and the management of risks to those factors during study conduct 3. Provide an overview of the types of CLINICAL STUDIES performed during the product lifecycle, and describe study design elements that support the identification of quality factors critical to ensuring the protection of study participants, the integrity of the data, the reliability of results, and the ability of the STUDIES to meet their objectives 4.

9 Provide a guide to the ICH efficacy documents to facilitate user's access GENERAL principles are described in Section 2 of this document, followed by a discussion of designing quality into CLINICAL STUDIES in Section 3. A broad overview of drug development planning and the information provided by different types of STUDIES needed to progress development through the lifecycle of the product is given in Section 4. In Section 5, important elements of CLINICAL study design are described that reflect the variety of designs used in drug development as well as the range of data sources available.

10 Section 6 addresses study conduct, ensuring the safety of study participants, and study reporting. Some CONSIDERATIONS for identifying factors that are critical to the quality of a study are provided in Section 7. The ICH Efficacy guidelines are an integrated set of guidance covering the planning, design, conduct, safety, analysis, and reporting of CLINICAL STUDIES . ICH E8 provides an overall introduction to CLINICAL development, designing quality into CLINICAL STUDIES and focusing on those factors critical to the quality of the STUDIES . The guidelines should be considered and used in an integrated, holistic way rather than focusing on only one guideline or subsection.